In the Margins
French pharmaceutical company Sanofi said it will seek to replace the board of Medivation after the American drug maker’s directors rejected a $9.3 billion takeover offer. Sanofi said in April that Medivation’s directors had failed to respond to its approach. Meanwhile, Medivation’s board called the offer “inadequate,” and founder and CEO David Hung has said the French company’s move was “opportunistically timed.” Read the original story from The New York Times.
Most Read
The JPMorgan Funds board has started off the New Year with new leadership following the retirement on Dec. 31 of Chairman Matthew Goldstein, who served in ...
The end of the decade is just weeks away, and mutual fund boards are looking ahead to 2020 and the issues and challenges that may land ...
The Securities and Exchange Commission should issue valuation guidance for investment companies. When I was chief counsel in the SEC's Division of Investment Management from 1997 ...
When a mutual fund board brings on a new independent director, the onboarding process can be all-encompassing (and many would argue it should be). Obviously, there ...